Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): Study protocol for a single arm, open-label, multicentre, phase II clinical trial

Bladder and urinary tract cancers account for approximately 21,000 new diagnoses and 5,000 deaths annually in the UK. Approximately 90% are transitional cell carcinomas where advanced disease is treated with platinum based chemotherapy and PD-1/PD-L1 directed immunotherapy.